Loading
Life sciences · Interventional Study
ClinicalTrials.gov · October 2, 2026
No summary has been generated for this record yet. What follows is drawn from its source metadata only.
Interventional Study.
No findings were extractable from the material analysed.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
This record has not been graded across any dimension yet. Treat the label above as provisional and read the source.
What is missing. This record has no bottom line, key findings, reported figures, evidence dimensions. That is a gap in the analysis, not a judgement about the study.
Registry record from ClinicalTrials.gov (NCT07854262). This is a study registration, not published results. Lead sponsor: Ankara City Hospital Bilkent. Recruitment status: RECRUITING. Phase: NA. Study type: INTERVENTIONAL. Enrollment: 48 participants (ESTIMATED). Conditions: Breast Cancer Related Lymphedema. Interventions: OTHER: Complete Decongestive Therapy; DEVICE: Extracorporeal Shock Wave Therapy. Primary outcome measures: Change in Upper-Extremity Circumference Difference , Baseline, immediately after completion of the 3-week treatment, 1 month after treatment, and 3 months after treatment.; Change in Upper-Extremity Volume , Baseline, immediately after completion of the 3-week treatment, 1 month after treatment, and 3 months after treatment.; Change in Skin and Subcutaneous Tissue Thickness Assessed by Ultrasonography , Baseline, immediately after completion of the 3-week treatment, 1 month after treatment, and 3 months after treatment.. Brief summary: The aim of this study is to evaluate the effectiveness of extracorporeal shock wave therapy (ESWT) combined with complete decongestive therapy (CDT) compared with CDT alone in patients with breast cancer-related lymphedema. Female patients with unilateral Stage II upper-extremity lymphedema related to breast cancer will be included. Participants will receive either complete decongestive therapy alone or complete decongestive therapy combined with extracorporeal shock wave therapy. Clinical outcomes will be evaluated before treatment, immediately after treatment, and at 1 and 3 months after treatment. Primary outcomes will include limb circumference difference, volumetric measurements, and ultrasonographic assessment of skin and subcutaneous tissue thickness. Secondary outcomes will include upper-extremity function, quality of life, and pain.